Clinical Trial Update: To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients

View source ↗

Summary

A completed clinical trial evaluating the prevalence of spasticity in relapsing-remitting multiple sclerosis and its impact on quality of life.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis, Relapsing Remitting | Status: COMPLETED